KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.
Kodiak Sciences reports positive topline results from BEACON Phase 3 study of tarcocimab in patients with retinal vein occlusion
Inflammatory bowel disease does not have ocular manifestations
Innovent announces first patient dosed in Phase 1 study of IBI324 in patients with diabetic macular edema
